ATE422556T1 - Hdac4- und hdac5-abhängige regulation der genexpression im herzen - Google Patents
Hdac4- und hdac5-abhängige regulation der genexpression im herzenInfo
- Publication number
- ATE422556T1 ATE422556T1 AT00955805T AT00955805T ATE422556T1 AT E422556 T1 ATE422556 T1 AT E422556T1 AT 00955805 T AT00955805 T AT 00955805T AT 00955805 T AT00955805 T AT 00955805T AT E422556 T1 ATE422556 T1 AT E422556T1
- Authority
- AT
- Austria
- Prior art keywords
- cardiac hypertrophy
- present
- hdac5
- hdac4
- heart
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15004899P | 1999-08-20 | 1999-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE422556T1 true ATE422556T1 (de) | 2009-02-15 |
Family
ID=22532889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00955805T ATE422556T1 (de) | 1999-08-20 | 2000-08-21 | Hdac4- und hdac5-abhängige regulation der genexpression im herzen |
Country Status (8)
Country | Link |
---|---|
US (3) | US6632628B1 (de) |
EP (1) | EP1210453B1 (de) |
JP (1) | JP2003507076A (de) |
AT (1) | ATE422556T1 (de) |
AU (1) | AU6794700A (de) |
CA (1) | CA2382045A1 (de) |
DE (1) | DE60041542D1 (de) |
WO (1) | WO2001014581A2 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2350086A1 (en) * | 1998-11-10 | 2000-05-18 | Board Of Regents, The University Of Texas System | Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor |
US6632628B1 (en) * | 1999-08-20 | 2003-10-14 | Board Of Regents, The University Of Texas System | Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression |
JP2001149081A (ja) * | 1999-11-29 | 2001-06-05 | Cyclex Co Ltd | 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法 |
AU2002338732A1 (en) * | 2001-09-19 | 2003-04-01 | Medigene Ag | Extracellular regulated kinase 2 (erk2) |
EP1605262A1 (de) * | 2001-09-27 | 2005-12-14 | Board Of Regents The University Of Texas System | Methode zur Idenfitikation von Inhibitoren der Herzhypertrophie |
US6706686B2 (en) | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
EP1443928B1 (de) | 2001-10-16 | 2011-07-27 | Sloan-Kettering Institute For Cancer Research | Behandlung von neurodegenerativen erkrankungen und krebs im gehirn |
US20030186289A1 (en) * | 2002-01-22 | 2003-10-02 | Myogen, Inc. | Model cell systems for screening of anti-hypertrophic therapeutics |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20040077083A1 (en) * | 2002-10-17 | 2004-04-22 | Isis Pharmaceuticals Inc. | Antisense modulation of histone deacetylase 4 expression |
US7169801B2 (en) | 2003-03-17 | 2007-01-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20060234245A1 (en) * | 2003-08-29 | 2006-10-19 | The Cleveland Clinic Foundation | Pathogenic gene for coronary artery disease |
EP1522857A1 (de) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2 |
EP1740945B1 (de) | 2004-04-07 | 2018-09-19 | Ncardia AG | Nichtinvasive, in-vitro-funktionelle gewebetestsysteme |
CA2565858C (en) * | 2004-05-11 | 2021-06-22 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
FI20040675A0 (fi) * | 2004-05-12 | 2004-05-12 | Orion Corp | Menetelmä sydämen hypertrofian hoitoon ja estoon |
EP1824831A2 (de) | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histondeacetylase-inhibitoren |
EP1896436A2 (de) | 2005-05-11 | 2008-03-12 | Takeda San Diego, Inc. | Inhibitoren der histondeacetylase |
JP2009501236A (ja) | 2005-07-14 | 2009-01-15 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
DK2056882T3 (da) * | 2006-08-01 | 2012-11-19 | Univ Texas | Identifikation af en mikro-rna, som aktiverer ekspression af en tung kæde med beta-myosin |
WO2010039697A2 (en) * | 2008-09-30 | 2010-04-08 | Gilead Sciences, Inc. | Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy |
EP2593121A2 (de) * | 2010-07-13 | 2013-05-22 | University Of Rochester | Camp/pka/hdac5-pfad und verwendungen davon |
US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
WO2012155070A1 (en) * | 2011-05-12 | 2012-11-15 | Salk Institute For Biological Studies | Modulation of lipid homeostatis, methods and compositions related thereto |
EP2763703B1 (de) | 2011-10-06 | 2018-02-14 | Miragen Therapeutics, Inc. | Steuerung von energiehomöostasen im ganzen körper durch mikro-rna regulierung |
EP3470536A1 (de) | 2013-10-01 | 2019-04-17 | The J. David Gladstone Institutes | Zusammensetzungen, systeme und verfahren zum wirkstoffscreening auf genexpressionsrauschen und verwendungen davon |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4367110A (en) | 1979-07-02 | 1983-01-04 | Toppan Printing Co. | Decorative laminate and a manufacturing method therefor |
US4452901A (en) | 1980-03-20 | 1984-06-05 | Ciba-Geigy Corporation | Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4668621A (en) | 1985-04-22 | 1987-05-26 | Wake Forest University | Detecting blood clotting factors with immobilized fibrinogen and labeled fibrinogen |
EP0273085A1 (de) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen |
US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
US4843867A (en) * | 1987-12-30 | 1989-07-04 | American Sterilizer Company | System for monitoring sterilant vapor concentration |
DK0517895T3 (da) | 1990-12-14 | 1997-04-07 | Univ California | Kimæriske kæder til receptorforbundne signaltransduktionsveje |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
AU4849593A (en) * | 1992-09-04 | 1994-03-29 | Children's Medical Center Corporation | Myocyte-specific transcription enhancing factor 2 |
US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
US5612455A (en) | 1994-07-05 | 1997-03-18 | Tularik, Inc. | Nuclear factors and binding assay |
US5600142A (en) * | 1995-05-26 | 1997-02-04 | Uop | Measurement of vaporized hydrogen peroxide |
US5872359A (en) * | 1995-07-27 | 1999-02-16 | American Sterilizer Company | Real-time monitor and control system and method for hydrogen peroxide vapor decontamination |
US5892229A (en) * | 1996-04-22 | 1999-04-06 | Rosemount Analytical Inc. | Method and apparatus for measuring vaporous hydrogen peroxide |
US6201165B1 (en) * | 1997-10-16 | 2001-03-13 | Board Of Regents, University Of Texas System | Transgenic animal models for cardiac hypertrophy and methods of use thereof |
AU753047B2 (en) * | 1997-11-14 | 2002-10-03 | Ethicon Inc. | Method for measuring the concentration of hydrogen peroxide vapor |
US6632628B1 (en) * | 1999-08-20 | 2003-10-14 | Board Of Regents, The University Of Texas System | Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression |
US6451272B1 (en) * | 1999-12-21 | 2002-09-17 | Ethicon, Inc. | Monitoring of sterilant apparatus and method for monitoring sterilant |
ES2237679T3 (es) * | 2001-05-11 | 2005-08-01 | Steris Inc. | Detector no dispersivo del infrarrojo medio para peroxido de hidrogeno vaporizado. |
WO2003006963A1 (en) * | 2001-07-10 | 2003-01-23 | Steris Inc. | Monitor and control using mid-infrared spectroscopy for vapor hydrogen peroxide processing technics |
US6847393B2 (en) * | 2002-04-19 | 2005-01-25 | Wren Technology Group | Method and system for monitoring point of sale exceptions |
US6946852B2 (en) * | 2003-03-14 | 2005-09-20 | Steris Inc. | Method and apparatus for measuring concentration of a chemical component in a gas mixture |
US6933733B2 (en) * | 2003-03-14 | 2005-08-23 | Steris Inc. | Method and apparatus for measuring the concentration of hydrogen peroxide in a fluid |
US6953549B2 (en) * | 2003-07-15 | 2005-10-11 | Steris Inc. | System and method for determining concentration of sterilant |
-
2000
- 2000-08-21 US US09/643,206 patent/US6632628B1/en not_active Expired - Fee Related
- 2000-08-21 AT AT00955805T patent/ATE422556T1/de not_active IP Right Cessation
- 2000-08-21 JP JP2001518892A patent/JP2003507076A/ja active Pending
- 2000-08-21 WO PCT/US2000/022958 patent/WO2001014581A2/en active Application Filing
- 2000-08-21 EP EP00955805A patent/EP1210453B1/de not_active Expired - Lifetime
- 2000-08-21 CA CA002382045A patent/CA2382045A1/en not_active Abandoned
- 2000-08-21 DE DE60041542T patent/DE60041542D1/de not_active Expired - Fee Related
- 2000-08-21 AU AU67947/00A patent/AU6794700A/en not_active Abandoned
-
2003
- 2003-08-08 US US10/637,403 patent/US7420100B2/en not_active Expired - Fee Related
-
2008
- 2008-09-02 US US12/231,311 patent/US20090087412A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001014581A9 (en) | 2002-09-06 |
US20050106654A1 (en) | 2005-05-19 |
EP1210453B1 (de) | 2009-02-11 |
AU6794700A (en) | 2001-03-19 |
JP2003507076A (ja) | 2003-02-25 |
CA2382045A1 (en) | 2001-03-01 |
US7420100B2 (en) | 2008-09-02 |
US6632628B1 (en) | 2003-10-14 |
EP1210453A2 (de) | 2002-06-05 |
DE60041542D1 (de) | 2009-03-26 |
WO2001014581A3 (en) | 2001-09-20 |
WO2001014581A2 (en) | 2001-03-01 |
US20090087412A1 (en) | 2009-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE422556T1 (de) | Hdac4- und hdac5-abhängige regulation der genexpression im herzen | |
DE69837295D1 (de) | Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1 | |
EA200500856A1 (ru) | Новые химические соединения | |
DE69805202D1 (de) | Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs | |
FR2714830B1 (fr) | Composition contenant des acides nucléiques, préparation et utilisations. | |
DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
ATE402698T1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
ATE188969T1 (de) | Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen | |
ATE279959T1 (de) | System zur regelung des herzrhythmus mit auswahl der elektroden | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
DE69715861T2 (de) | Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression | |
EA200000723A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
BR9908280A (pt) | Inibidores de enzimas de fosfolipase | |
MD970253A (ro) | Inhibitori biciclici micromoleculari ai trombinei | |
DE69735442D1 (de) | Antidiabetische mittel | |
EA200200390A1 (ru) | Новые оксабиспидиновые соединения, полезные при лечении сердечных аритмий | |
DE3588023D1 (de) | Mittel zur Behandlung von Herzerkrankungen. | |
ATE232873T1 (de) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
PT888327E (pt) | Derivados de benzopirano que possuem uma accao antagonistica dos leucotrienos | |
EA199600078A1 (ru) | Новый хелатообразователь железа как ингибитор процесса окисления, опосредованного железом | |
DE69737062D1 (de) | Gentherapie für kongestives herzversagen | |
ATE297739T1 (de) | Endothelin-antagonisten zur behandlung von herzversagen | |
DE69924979D1 (de) | Behandlung von chronischen schmerzen | |
DE602004016547D1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
GB2346146A (en) | Calcineurin-dependent control of skeletal muscle fiber type |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |